CA3204755A1 - Use of link-tsg6 for the treatment of osteoarthritic pain - Google Patents

Use of link-tsg6 for the treatment of osteoarthritic pain Download PDF

Info

Publication number
CA3204755A1
CA3204755A1 CA3204755A CA3204755A CA3204755A1 CA 3204755 A1 CA3204755 A1 CA 3204755A1 CA 3204755 A CA3204755 A CA 3204755A CA 3204755 A CA3204755 A CA 3204755A CA 3204755 A1 CA3204755 A1 CA 3204755A1
Authority
CA
Canada
Prior art keywords
pain
link
tsg6
binding activity
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204755A
Other languages
English (en)
French (fr)
Inventor
Anthony Day
Caroline Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Publication of CA3204755A1 publication Critical patent/CA3204755A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3204755A 2021-01-20 2022-01-19 Use of link-tsg6 for the treatment of osteoarthritic pain Pending CA3204755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100761.2A GB202100761D0 (en) 2021-01-20 2021-01-20 Treatment of osteoarthritic pain
GB2100761.2 2021-01-20
PCT/EP2022/051101 WO2022157181A1 (en) 2021-01-20 2022-01-19 Use of link-tsg6 for the treatment of osteoarthritic pain

Publications (1)

Publication Number Publication Date
CA3204755A1 true CA3204755A1 (en) 2022-07-28

Family

ID=74679050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3204755A Pending CA3204755A1 (en) 2021-01-20 2022-01-19 Use of link-tsg6 for the treatment of osteoarthritic pain

Country Status (8)

Country Link
US (1) US20250121028A1 (enExample)
EP (1) EP4281098A1 (enExample)
JP (1) JP7896251B2 (enExample)
KR (1) KR20230142502A (enExample)
CN (1) CN116744958A (enExample)
CA (1) CA3204755A1 (enExample)
GB (1) GB202100761D0 (enExample)
WO (1) WO2022157181A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910645D0 (en) 2019-07-25 2019-09-11 Univ Manchester Treatment for dry eye disease
GB202416087D0 (en) 2024-10-31 2024-12-18 Link Biologics Treatment of ocular disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9878003B2 (en) * 2006-03-06 2018-01-30 The University Of Manchester Method of treating bone disorders using TSG-6
CN104703146B (zh) 2013-12-09 2019-03-08 腾讯科技（深圳）有限公司 信息推送方法、客户端及系统

Also Published As

Publication number Publication date
EP4281098A1 (en) 2023-11-29
KR20230142502A (ko) 2023-10-11
GB202100761D0 (en) 2021-03-03
US20250121028A1 (en) 2025-04-17
JP7896251B2 (ja) 2026-07-29
CN116744958A (zh) 2023-09-12
JP2024504683A (ja) 2024-02-01
WO2022157181A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
CN101505787B (zh) 软骨障碍的治疗
IL197169A (en) Use of 18 fgf in the manufacture of a drug for the treatment of cartilage disorders
AU2015220773B2 (en) FGF-18 compound dosing regimen
US20250121028A1 (en) Use of link-tsg6 for the treatment of osteoarthritic pain
KR20190132552A (ko) 성장 호르몬 단편들의 사용
Zhang et al. Possible mechanism of static progressive stretching combined with extracorporeal shock wave therapy in reducing knee joint contracture in rats based on MAPK/ERK pathway
ES2242858T3 (es) Utilizacion de toxina botulinica para obtener un producto que se utiliza en patologias articulares, particularmente coxartrosis, epicondilitis y patologia de la capsula de los musculos rotadores.
ES3052874T3 (en) Composition comprising sodium hyaluronate and amino acids for use in the orthopedic field
AU2002222432A1 (en) Use of botulinum toxin for treatment of articular pathologies
EP2502632B1 (en) Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis
Rajalaxmi et al. Efficacy of Dynamic VS Closed Kinematic Exercise Combined with Stretching in Adhesive Capsulitis-a double blinded randomized controlled trial
Nikolova et al. Degenerative joint diseases (osteoartrtrosis) and quality of life
US20220184180A1 (en) Treatment of patients at risk of rapid progression of osteoarthritis
US20200222454A1 (en) New therapy for osteoarthritic pain
US20040082516A1 (en) Compositions for promoting nerve regeneration
HK40109892A (en) Composition comprising sodium hyaluronate and amino acids for use in the orthopedic filed
Bellile Musculoskeletal Disorders
Capodaglio et al. Poster 128: Functional Evaluation of the Spine in Obese Women With Low Back Pain: Is Kinematic Useful?
Rivera et al. 543 VISCOSUPPLEMENTATION FOR THE TREATMENT OF HIP OSTEOARTHRITIS
Nalamachu Poster 125: Cancelled.
Dholakia et al. Poster 127: Femoral Neuropathy Caused by Enlarged Iliopsoas Bursa: A Case Report
Cohen et al. This chapter will familiarize the reader with the most common disorders involving the
Chhatre et al. Poster 126: Evaluate the Efficacy of BotulinumToxin Type A for the Symptomatic Relief of Pain and Paresthesias in Mild-to-Moderate Carpal Tunnel Syndrome: A Case Series

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250131

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250709

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250716

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251027

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251027

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260115

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260210

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260219

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728